Navigating Later-Line Therapies for Progressive Urothelial Cancer
A key opinion leader delves into the intricacies of second-line and third-line treatment sequencing for patients with progressive disease, addressing the appropriate timing for repeat testing and elaborating on the critical factors that inform their personalized treatment approach.
- Briefly discuss second-line treatment options and rationale. Upon progression, what is your approach to management? Do you repeat testing at this point?
- Discuss the available third line and later treatment options. How do you discuss these options with patients?
- What factors influence your decision to use sacituzumabgovitecan or enfortumab vedotin (e.g. comorbidities, prior treatment tolerance, biomarkers, metastasis site)?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
